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I. INTRODUCTION 
 Baraclude
®
, a hepatitis B drug marked by Bristol-Myers Squibb Co. (BMS), has an active 
ingredient of a chemical compound, entecavir.
1
 Entecavir is composed of two regions: a 
carbocyclic ring and a guanine base, and it is covered by a patent owned by BMS.
2
 Teva 
Pharmaceuticals USA, Inc. (Teva) challenged the patent’s validity during an infringement 
litigation brought by BMS.
3
 Teva presented a known compound 2’-CDG and claimed entecavir 
was obvious over 2’-CDG.4 Entecavir and 2’-CDG are structurally similar, the only difference 
being a carbon-carbon double bond (an exocyclic methylene group) at the 5’ position of the 
carbocyclic ring in entecavir.
5
 Teva contended a person having ordinary skill in the art 
(PHOSITA) would have been motivated to select 2’-CDG as a lead compound for further 
development and would have been motivated to modify the lead compound to arrive at the 
claimed compound, so entecavir was obvious and unpatentable.
6
 
 This case is an illustration of the application of the Lead Compound Analysis (LCA) in 
the determination of patentability of new chemical compounds on obviousness ground, 
especially chemical compounds in pharmaceutical patents. The LCA was established by the U.S. 
Court of Appeals for the Federal Circuit (Federal Circuit) in 2000 and has been applied by courts 
and the United State Patent and Trademark Office (USPTO) since then. Its continued application 
after the United State Supreme Court’s decision in KSR Int'l Co. v. Teleflex Inc.7 has been 
                                                        
1
 Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 752 F.3d 967, 969 (Fed. Cir. 2014) 
2
 Id. 
3
 Id. at 970. 
4
 Id. 
5
 Id. at 969-70. 
6
 Id. at 970. See also Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 923 F. Supp. 2d 602, 
613 (D. Del. 2013), aff'd, 752 F.3d 967 (Fed. Cir. 2014). 
7
 550 U.S. 398 (2007). 
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criticized widely as rigid and inconsistent with the KSR rationale.
8
 This article explains the 
doctrine of Lead Compound Analysis and its application in the termination of obviousness of 
new chemical compounds in court litigations and USPTO proceedings, and argues that the LCA 
is proper and consistent with the rationale under the KSR. Part II provides the background of the 
drug discovery process and emphasizes the high intellectual requirement during modern drug 
discovery. Part III explains the general obviousness standard under the statute and the Supreme 
Court decisions and summarizes the historical development of the obviousness standard in 
chemical art. Part IV discusses the doctrine of LCA and its application in court litigations and the 
USPTO proceedings, and analyzes the difference of its application between courts and USPTO 
proceedings. Part V argues the LCA is determined by the drug discovery process and is 
consistent with the KSR rationale. Part VI concludes the analysis on the LCA. 
II. Development of Drug Discovery 
Drug discovery traditionally was based on the nature’s bounty and imagination of 
chemists. After a serendipitous biological finding, scientists engaged in serial purification of the 
crude extracts to obtain the active principle.
9
 These compounds had unknown target and their 
mechanism of action were usually unknown. They were further modified to obtain simpler and 
more bioavailable compounds based on the core structure of the active compounds.
10
 The 
discovery and development of Penicillin and related antibiotics is an example of such 
serendipitous discovery and development. Penicillin was discovered in 1929 as a metabolite 
                                                        
8
 Briana Barron, Structural Uncertainty: Understanding the Federal Circuit's Lead Compound 
Analysis, 16 Marq. Intell. Prop. L. Rev. 401, 403 (2012); Vincent L. Capuano, Obviousness of 
Chemical Compounds: The “Lead Compound” Concept, Intell. Prop. Today July 2007, at 33.  
9
 Leland J. Gershell, Joshua H. Atkins, A brief history of novel drug discovery technologies, 2 
Nature Revs. Drug Discovery 321 (2003), 
http://www.nature.com/nrd/journal/v2/n4/pdf/nrd1064.pdf. 
10
 Id. 
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from a penicillium mold by Alexander Fleming when he was sorting through petri dishes 
containing bacteria that caused boils, sore throats and abscesses, and noticed something unusual 
on one dish.
11
 Then in 1938, Howard Florey, Ernst Chain and their colleagues chose penicillin 
for further study.
12
 After time-consuming extraction, purification, trial and production, penicillin 
became the most widely used antibiotic.
13
 It opened the door to the discovery of other antibiotics 
and started a new era of bacterial infection treatment.
14
 
With the development of chemistry, pharmacology, microbiology, and biochemistry, 
drug discovery became target oriented, and the understanding of biological structure and 
function leads to the creation of novel chemical structures suitable as drugs.
15
 The modern drug 
discovery is a complicated process. It starts with the identification of a disease relevant target, 
which can be proteins, genes, or RNA.
16
 “A ‘druggable’ target is accessible to the putative drug 
molecule, be that a small molecule or larger biologicals and upon binding, elicit a biological 
response which may be measured both in vitro and in vivo.”17 Available biomedical data is useful 
in the target identification.
18
 This target is further validated through antisense technology, 
chemical genomics or other technologies.
19
 Following the target identification and validation is 
                                                        
11
 The discovery and development of penicillin 1928-1945, commemorative booklet produced by 
the National Historic Chemical Landmarks program of the American Chemical Society in 1999 
(PDF), 
https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html. 
12
 Jürgen Drews, Drug Discovery: A historical Perspective, 287 Science1960, 1960 (Mar. 17, 
2000), http://science.sciencemag.org/content/287/5460/1960.full. 
13
 Supra note 11. 
14
 Supra note 12. 
15
 Id. 
16
 JP Hughes, S Rees, SB Kalindjian, and KL Philpott, Principles of early drug discovery, 162 
Brit. J Pharmacology 1239, 1239 (2011 Mar), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058157/. 
17
 Id.  
18
 Id. at 1240. 
19
 Id. at 1240-42. 
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the hit identification and lead discovery phase of the drug discovery.
20
 High throughput 
screening (HTS) was developed to identify molecules that elicit a positive response with the drug 
target.
21
 It involves the screening of large numbers of compounds against the drug target in 
various assay systems such as biochemical assays or cell-based assays.
22
 These compounds 
represent “numerous variations on a few chemical themes or… fewer variations on a greater 
number of themes in high-throughput configurations.”23 Numerous data are developed for 
potency, selectivity and other properties of compounds, and chemistry programs are employed to 
improve the properties to support the hypothesis that intervention at the drug target will lead to 
the effective treatment of the disease.
24
  
Once a number of hits are obtained, further analysis, screening, and various assays are 
carried out to narrow the number of hits to produce lead compounds.
25
 In addition to properties 
like potency and selectivity, absorption, distribution, metabolism and excretion (ADME) 
properties as well as physicochemical and pharmacokinetic (PK) data are collected to help refine 
the hits.
26
 During the process, the compounds may be modified to yield more potent and 
selective leads with desirable PK properties.
27
 The lead compounds are then further optimized to 
achieve the favorable properties while improving on deficiencies in the lead structures.
28
  
                                                        
20
 Id. at 1242. 
21
 Id. 
22
 Id. at 1242-43. 
23
 Drews, supra note 12, at 1962. 
24
 Hughes, supra note 16, at 1242. 
25
 Id. at 1245-48. 
26
 Id. at 1246. 
27
 Id. at 1246-48. 
28
 Id. at 1248. 
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The whole process of screening to lead generation and optimization is a series of time-
consuming and intellectually intense activities within the pharmaceutical industry.
29
 Typically, 
each project starts with 200,000 to >1,000,000 compounds to be screened, and the number is 
reduced to 100’s and then down to one or two candidates, following hit-to-lead and lead 
optimization process.
30
 “There are rarely any short cuts and significant, intellectual input is 
required from scientists from a variety of disciplines and backgrounds. The quality of the hit-to-
lead starting point and the expertise of the available team are the key determinants of a 
successful outcome of this phase of work.”31  
III. Obviousness Standard and Its Historical Development in Chemical Art 
 Under the U.S. patent law, to be patentable, a claimed invention has to be a process, 
machine, manufacture, or composition of matter that is useful, novel and nonobvious.
32
 The 
Supreme Court has interpreted the statute and set forth the standard for obviousness 
determination for all cases. The obviousness standard in chemical art has been focused on the 
structural similarity of chemicals. 
A. The Foundation of the Obviousness Standard 
The general obviousness standard applicable to all patents are set forth in the statute and 
the U.S. Supreme Court decisions in Graham v. John Deere Co. of Kansas City
33
 and KSR Int'l 
Co. v. Teleflex Inc.
34
  
Under 35 U.S.C. § 103, a claimed invention is obvious “if the differences between the 
claimed invention and the prior art are such that the claimed invention as a whole would have 
                                                        
29
 Id. at 1242, 1248. 
30
 Id. at 1248. 
31
 Id.  
32
 35 U.S.C. § 102-103. 
33
 383 U.S. 1 (1966). 
34 550 U.S. 398 (2007). 
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been obvious before the effective filing date of the claimed invention to a person having ordinary 
skill in the art.”35 The U.S. Supreme Court examined the statute and laid out the standard for the 
obviousness determination in Graham.
36
 The obviousness of a subject matter should be assessed 
according to the scope and content of the prior art, the difference between the prior art and the 
claimed invention, the level of the ordinary skill in the art, any secondary considerations such as 
commercial success, long felt but unsolved needs, and failure of others.
37
 
To implement this obviousness standard, the Federal Circuit had developed a teaching, 
suggestion, or motivation (TSM) test.
38
 Under this test, there has to be some teaching, motivation 
or suggestion in the prior art itself, the nature of the problem or knowledge of a PHOSITA to 
combine the elements of prior art to render the claimed invention obvious.
39
 The TSM provided 
some certainty and predictability in the lower courts in applying the obviousness standard set 
forth by the Supreme Court.
40
 It was also criticized as imposing a higher standard on patent 
challengers and being inconsistent with section 103 or Graham.
41
 
In 2007, the Supreme Court decided KSR Int'l Co. v. Teleflex Inc., and rejected Federal 
Circuit’s TSM test as the exclusive test for obviousness.42 In KSR, Teleflex Inc. (Teleflex) was 
the exclusive licensee of a patent claiming an adjustable electronic pedal assembly with an 
electronic pedal position sensor attached to a fixed pivot point of the assembly for vehicles.
43
 
Teleflex sued KSR International Company (KSR) for infringement of this patent after KSR 
                                                        
35
 35 U.S.C. § 103. 
36
 383 U.S. at 13-18. 
37
 Id. at 17. 
38
 KSR, 550 U.S. at 399. 
39
 Id. 
40
 James Skelley, Teaching-Suggestion-Motivation Under Review: Developments in KRS 
International Co. v. Teleflex, Inc., 13 B.U. J. Sci. & Tech. L. 107, 118 (2007). 
41
 Id. at 110, 114-117. 
42
 550 U.S. at  415. 
43
 Id. at 410-11. 
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combined an adjustable pedal system with electronic throttle control.
44
 KSR countered that the 
patent claim was invalid for obviousness.
45
 The district court granted KSR’s summary judgment 
on the ground of obviousness because the prior art taught every element of the claim and the 
prior art and the state of the industry provided suggestion or motivation to combine the 
elements.
46
 The Federal Circuit reversed and ruled the district court did not apply the TSM test 
strict enough.
47
 The Federal Circuit found the prior art did not address the exact problem the 
patentee was trying to solve, and there was not sufficient motivation or suggestion for a 
PHOSITA to combine the electronic sensor on the adjustable pedal system.
48
 
The Supreme Court reversed and held the combination of the existing elements was a 
design step well within a PHOSITA’s knowledge and the benefit of doing so was obvious.49 The 
Court found such a combination of existing elements according to known methods yielded 
predictable benefits, and the marketplace would have incentivized a PHOSITA to make such 
combination.
50
 The Court opined that interrelated teachings of prior art references, demands 
known to the design community or the marketplace, any need or problem know in the field and 
addressed by the patent, and the background knowledge of a PHOSITA were necessary in 
determining whether there was a reason or motivation to combine the known elements.
51
 
Common sense could also direct a PHOSITA to look beyond the primary purpose of familiar 
items and fit prior art teachings together.
52
 In addition, if “there is a design need or market 
                                                        
44
 Id.  
45
 Id. at 405. 
46
 Id. at 412-13. 
47
 Id. at 413-14. 
48
 Id. at 414. 
49
 Id. at 427-28. 
50
 Id. at 422-25. 
51
 Id. at 418, 420. 
52
 Id. at 420. 
  8 
pressure to solve a problem and there are a finite number of identified, predictable solutions,” it 
is obvious for a PHOSITA to try the combination, and “[i]f this leads to the anticipated success, 
it is likely the product not of innovation but of ordinary skill and common sense.”53 The KSR 
decision returned the obviousness analysis to a flexible approach. 
B. Historical Development of the Obviousness Doctrines in Chemical Art 
In the determination of patentability under obviousness ground, the procedural 
mechanism includes the establishment of a prima facie obviousness. A patent examiner, or in the 
case a party who challenges the patented claim for obviousness, has the initial burden to establish 
any prima facie conclusion of obviousness.
54
 If the examiner or the party establishes such case, 
the burden shifts to the patent applicant or owner to rebut the obviousness showing.
55
 The 
rebuttal evidence includes “comparative test data showing that the claimed invention possesses 
improved properties not expected by the prior art.”56 Early cases involving obviousness of new 
chemical compounds focused on the standard of the prima facie obviousness. Under the third 
Graham factor, prima facie obviousness “generally turns on the structural similarities and 
differences between the claimed compound and the prior art compounds.”57 
The early doctrine of obviousness for chemical compounds was set forth in the “Haas-
Henze” cases, decisions by the U.S. Court of Customs and Patent Appeals (CCPA) in In re Haas 
                                                        
53
 Id. at 421. 
54
 2142 Legal Concept of Prima Facie Obviousness (R-07.2015), MPEP s 2142; § 
9:74.Generally—Properties of chemical compositions—prima facie, or structural obviousness, 3 
Moy's Walker on Patents § 9:74 (4th ed.). 
55
 2142 Legal Concept of Prima Facie Obviousness (R-07.2015), MPEP s 2142 
56
 Id. 
57
 Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280, 1291 (Fed. Cir. 2012) (Citing Daiichi 
Sankyo Co. v. Matrix Labs., Ltd., 619 F.3d 1346, 1352 (Fed.Cir.2010). 
  9 
and In re Henze.
58
 Under the “Haas-Henze” doctrine, if a claimed chemical compound is 
structurally similar to a prior art compound, there is a presumption of obviousness (older term of 
prima facie obviousness) because of the assumption that structurally similar compounds have 
similar properties.
59
 This presumption could be rebutted “by a showing that the claimed 
compound possesses unobvious or unexpected beneficial properties not actually possessed by the 
prior art” compound.60 This doctrine was later overruled and a new standard was announced in In 
re Dillon.
61
 
 In In re Dillon, Dillon’s patent application related to hydrocarbon fuel compositions 
containing certain tetra-orthoesters, and the patent application disclosed that the compositions 
were useful in reducing the emission of solid particulates during combustion of the fuel.
62
 The 
USPTO rejected all the claims directed to the compositions and method for obviousness over 
three prior art patents, U.S. Patent Number 4,390,417 (‘417 patent), 4,395,267 (‘267 patent), and 
3,903,006 (‘006 patent).63 The ‘417 patent disclosed hydrocarbon fuel compositions containing 
chemical compounds including tri-orthoesters, useful for dewatering fuels.
64
 The ‘267 patent 
described hydrocarbon fuel composition containing alcohol immiscible with the fuel, and tri-
orthoesters.
65
 The tri-orthoester serves as a cosolvent to make the whole composition a single 
phase.
66
 The ‘006 patent disclosed and suggested that tri-orthoesters and tetra-orthoesters were 
                                                        
58
 In re Hass, 141 F.2d 122, 124 (C.C.P.A. 1944); Application of Henze, 181 F.2d 196 (C.C.P.A. 
1950) overruled by Application of Stemniski, 444 F.2d 581 (C.C.P.A. 1971). 
59
 See Guttag, The Hass-Henze Doctrine, 43 JPOS 808 (1961). 
60
 Henze, 181 F.2d at 201. 
61
 919 F.2d 688 (Fed. Cir. 1990). 
62
 Id. at 690. 
63
 Id. at 691. 
64
 Id. 
65
 Id. 
66
 Id. 
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equivalent in their use to remove water from hydraulic fluids.
67
 However, none of the prior art 
disclosed the combination of hydrocarbon fuel with tetra-orthoester and their use in reducing 
particulate emissions recited in Dillon’s patent application.68  
The Federal Circuit affirmed the PTO’s rejection of the claims on the obviousness 
ground.
69
 The court found there was a close relationship between tri- and tetra-orthoesters in the 
fuel oil art, so there was a reasonable expectation the tri-and tetra-oethoester compositions would 
have similar properties.
70
 This would have created sufficient motivation for a PHOSITA to make 
a new composition containing tetra-orthoesters.
71
 Therefore, a prima facie case of obviousness 
had been made.
72
 Although the new use was not described or suggested in any prior art, this did 
not defeat the prima facie case, and the composition claims were not limited to the new use.
73
 
Unless Dillon could rebut the prima facie case of obviousness with some unexpected advantage 
or properties, the claims were unpatentable for obviousness.
74
 
Therefore, the Dillon court formulated the new standard of prima facie obviousness for 
chemical art. Under the standard, a chemical compound or composition is prima facie obvious if 
the compound or composition is structurally similar to the prior art, and the art provides any 
reason or motivation to make the claimed compound or composition.
75
 The prima facie 
obviousness can be rebutted by unexpected properties not present in the prior art, by no 
                                                        
67
 Id. 
68
 Id. 
69
 Id. at 695. 
70
 Id. at 692. 
71
 Id.  
72
 Id. at 693. 
73
 Id. at 692-93.  
74
 Id.  
75
 Id. at 692. 
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motivation in the prior art, or by other relevant argument.
76
 The Dillon court specifically rejected 
the requirement that the prior art provides some suggestion or expectation that the new 
compound or composition has the same or a similar utility.
77
 Under the Dillon standard, any 
motivation that suggests modification of the prior art compound or composition into the claimed 
invention would be sufficient for a prima facie showing of structural obviousness.
78
 The Dillon 
prima facie obviousness standard is still good law and is still applied by courts and the USPTO. 
IV. Lead Compound Analysis 
The Lead Compound Analysis was established by the Federal Circuit in 2000 in 
Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc.
79
 It has been used for the determination of 
whether a new chemical compound would have been prima facie obvious over prior art 
compounds by courts since then, especially new chemical compounds in pharmaceutical patents. 
The USPTO has also applied the LCA in various proceedings. 
The “lead compound” in the LCA is defined as “a compound in the prior art that would 
be most promising to modify in order to improve upon its . . . activity and obtain a compound 
with better activity,”80 and it is “a natural choice for further development efforts.”81 The analysis 
follows a two-step inquiry.
82
 First, the court determines whether a PHOSITA would have 
selected the prior art compounds as lead compounds for further development.
83
 Second, the court 
determines whether some reason or motivation would have prompted the PHOSITA to modify 
                                                        
76
 Id.  
77
 Id.  
78
 § 9:74.Generally—Properties of chemical compositions—prima facie, or structural 
obviousness, 3 Moy's Walker on Patents § 9:74 (4th ed.). 
79
 231 F.3d 1339 (Fed. Cir. 2000). 
80
 Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed. Cir. 2007) 
81
 Altana Pharma AG v. Teva Pharms. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir. 2009). 
82
 Otsuka, 678 F.3d at 1291. 
83
 Id.  
  12 
the lead compounds to make the claimed compounds with a reasonable expectation of success.
84
 
A. Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc. 
The chemical compound at issue in Yamanouchi is famotidine (see structure below), for 
treating heartburn and ulcers.
85
 It belongs to a class of inhibitors of stomach acid secretion.
86
 
Yamanouchi Pharmaceutical Co., Ltd. and Merck & Co., Inc. (Yamanouchi) owned a U.S. 
Patent No. 4,283,408 (‘408 patent) claiming famotidine for treating heartburn and ulcers.87 
Danbury Pharmacal, Inc. (Danbury) filed an Abbreviated New Drug Application (ANDA) with 
the Food and Drug Administration (FDA) for approval of making generic famotidine.
88
 The 
application also included a paragraph IV certification, which inserted the patent was invalid or 
would not be infringed by the drug for which the approval was sought.
89
 Under the Drug Price 
Competition and Patent Term Restoration Act, also known as the Hatch–Waxman Act, the filing 
of a paragraph IV certification is treated as a technical act of patent infringement.
90
 Yamanouchi 
then filed suit against Danbury for patent infringement under 35 U.S.C. § 271(e)(2)(A).
91
 The 
district court ruled that Danbury did not show by clear and convincing evidence that the ‘408 
patent was obvious at the time of the invention.
92
 
 On appeal, the Federal Circuit affirmed.
93
 It first examined the history of the 
development of this drug, and noted that out of 11,000 compound candidates of this class of 
compounds synthesized by pharmaceutical companies, four were eventually approved by the 
                                                        
84
 Id. at 1292. 
85
 231 F.3d at 1341. 
86
 Id.  
87
 Id.  
88
 Id. at 1342. 
89
 Id.  
90
 21 U.S.C. § 271(e)(2). 
91
 Yamanouchi, 231 F.3d at 1342. 
92
 Id. 
93
 Id. at 1348. 
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FDA.
94
 The Federal Circuit then examined the prior art compounds Danbury presented for its 
obviousness argument.
95
 Danbury argued one of ordinary skill in the art would consider it 
obvious to select the example 44 from a prior art patent as a lead compound, and replace the left 
side ring with the ring structure from tiotidine, a known failed compound in the 11,000 
candidates, and finally substitute the CONH group in example 44 with a SO2NH2 group to create 
famotidine.
96
  
 
Famotidine: 
N
S
H2C S C
H2
C
H2
C NH2
N
NC
H2N
H2N
SO2NH2
 
 
Example 44: 
HN N
H2C S C
H2
C
H2
C NH2
N CONH2
H3C
 
 
 
                                                        
94
 Id. at 1341-42. 
95
 Id. at 1343-45. 
96
 Id.  
  14 
Tiotidine:  
N
S
H2C S C
H2
C
H2
C N
H
N
NC
H2N
H2N
C
CH3
N
  
 
The Federal Circuit found there was no motivation for a person of skill in the art to select 
the prior art compounds Danbury presented.
97
 The fact that Example 44 was three times more 
active than cimetidine (a benchmark compound at the time of invention) was not a sufficient 
motivation, since other prior art references disclosed compounds with activities of ten times 
higher than cimetidine.
98
 Therefore, Example 44 was not an obvious choice.
99
 
The Federal Circuit also found there was no motivation to replace the left side ring in 
example 44 with the ring structure from tiotidine and then substitute the CONH2 group because 
there was no reasonable expectation of success.
100
 An expected baseline level of activity, which 
is a merely 1/165th the activity of cimetidine, was not a motivation for a reasonable expectation 
of success.
101
 The reasonable expectation required finding a compound with high activity, few 
side effects, and lacked toxicity.
102
 
                                                        
97
 Id. at 1345. 
98
 Id.  
99
 Id. 
100
 Id. 
101
 Id. 
102
 Id. 
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The court also noted there was no motivation for a person of ordinary skill to pursue the 
precise steps required to achieve the invention.
103
 A slight change of order of the steps would 
result in a compound of much reduced activity, resulting teaching away from famotidine.
104
 
Therefore, it would not have been obvious to follow the specific steps to arrive at the 
invention.
105
 
B. Lead Compound Analysis in Courts Litigations 
The application of LCA in court litigations has been focused on the determination of 
obviousness of chemical compounds in pharmaceutical patents. The reason or motivation for a 
PHOSITA to select a prior art compound as the lead compound is critical in the determination.  
1. Motivation to Select 
In applying the first prong of the LAC, the Federal Circuit has considered various factors 
to determine whether a PHOSITA would have selected a prior art compound as the lead 
compound. 
i. Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd. 
In Takeda, the Federal Circuit found a structurally close prior compound would not be 
considered by a PHOSITA as a lead compound because of its adverse effect.
106
 In this case, 
Takeda Chemical Industries, LTD and Takeda Pharmaceuticals North America, Inc. (Takeda) 
developed the drug ACTOS
®
 for Type 2 diabetes, which contained the active ingredient 
pioglitazone.
107
 This chemical compound was covered in the U.S. Patent 4,687,777 (the “′777 
patent”), directed to “antidiabetic agents having a broad safety margin between pharmacological 
                                                        
103
 Id.  
104
 Id. 
105
 Id. 
106
 492 F.3d at 1360. 
107
 Id. at 1352-53. 
  16 
effect and toxicity or unfavorable side reactions.”108 Alphapharm Pty., Ltd. (Alphapharm) filed 
an ANDA and challenged the validity of the patent for obviousness over a prior art compound, 
compound b.
109
 Alphapharm asserted compound b was structurally similar to pioglitazone and 
was the most effective antidiabetic compound in the prior art at the time of the invention, so a 
PHOSITA would have selected compound b as the lead compound.
110
 The district court found 
there was no motivation to select compound b as the lead compound and the prior art taught 
away from its use as antidiabetic agent.
111
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The Federal circuit agreed and noted the prior art patent (‘200 patent) disclosed hundreds 
of millions of compounds, including compound b.
112
 Although ‘200 patent specifically identified 
fifty-four compounds synthesized, it did not disclose any experimental data or test results.
113
 The 
prosecution history of the ‘200 patent revealed test results of compound b along with other eight 
compounds, but the court noted the information was provided in response to a rejection to show 
compounds in ‘200 patent were superior over known compounds.114 The court therefore found 
there was no suggestion to a PHOSITA that the nine compounds in the prosecution history were 
best candidates for antidiabetic research. Further, the court noted another prior art article 
disclosed hypoglycemic activity of 101 compounds, including compound b.
115
 The article 
specifically identified three compounds as most favorable compounds, and compound b was not 
one of them.
116
 Instead, the article singled out compound b as causing “considerable increase in 
body weight and brown fat weight.”117 The court thus believed that the negative properties would 
have directed a PHOSITA away from selecting compound b as the lead compound.
118
 
ii. Otsuka Pharm. Co. v. Sandoz, Inc. 
In Otsuka, the Federal Circuit stressed the importance of a compound’s pertinent property 
in guiding a PHOSITA to select a lead compound.
119
 The compound at issue is aripiprazole, the 
active ingredient in the antipsychotic drug Abilify
®
, for the treatment of schizophrenia, bipolar 
disorder, irritability associated with autistic disorder in pediatric patients.
 120
 ANDA filers 
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challenged the patent covering aripiprazole for obviousness over three prior art compounds, 
unsubstituted butoxy, 2,3-dichloro propoxy, and OPC-4392.
121
 The three compounds are all 
structurally similar to aripiprazole. However, the unsubstituted butoxy lacks the 2,3-dichloro 
substituent on the pheny ring; the 2,3-dichloro propoxy has a propoxy linker instead of a butoxy 
linker; and the OPC-4392 is different on the 3,4-dihydrocarbostyril ring and the substituents on 
the phenyl ring (see structures below). The Federal Circuit examined the properties of the prior 
art compounds, and affirmed the district court that the ANDA filers failed to prove by clear and 
convincing evidence that a PHOSITA would have selected these compounds as lead compounds 
for their obviousness claim.
122
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“Unsubstituted butoxy”: 
N
H
O (CH2)4 N NO
butoxy linker  
 
OPC-4392: 
N
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For the 2,3-dichloro propoxy, the Federal Circuit noted this compound was buried in 
hundreds of examples that might be useful for central nervous system controlling properties, and 
the prior art did not provide motivation to narrow the examples to the 2,3-dichloro propoxy 
compound.
123
 The court rejected the argument that a generic disclosure is enough for 
obviousness.
124
  
For the unsubstituted butoxy compound, the Federal Circuit noted it was among nine 
trillion compounds claimed in the prior art, with a “laundry list” of potential central nervous 
system controlling properties.
125
 Although there was some mouse jumping test data on the 
unsubstituted butoxy compound, along with other ten compounds,
126
 the data showed four 
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compounds had greater potency than the unsubstituted butoxy compound, and all four 
compounds had a propoxy linker, with one compound being ten times more potent than the 
unsubstituted butoxy compound.
127
  
The court also rejected the OPC-4392 as a lead compound because the prior art taught 
away from selecting OPC-4392 as a lead compound.
128
 Although a prior art reference stated 
OPC-4392 was an antipsychotic drug, and OPC-4392 proceeded to the Phase II clinic trials, the 
same reference also stated the activity was not strong, and the drug was likely to cause patients to 
act out on their delusions and hallucinations.
129
 Other references cautioned on the sever side 
effects of OPC-4392 in low doses.
130
 Therefore, based on the totality of the prior art, OPC-4392 
would not have been selected as a lead compound.
131
  
In emphasizing “‘[p]otent and promising activity in the prior art trumps mere structural 
relationships,’” the Federal Circuit concluded that ANDA filers failed to prove aripiprazole 
would have been obvious over the asserted prior art compounds, and their obviousness argument 
was based on impermissible hindsight reasoning.
132
 
iii. Eisai Co. v. Dr. Reddy's Labs., Ltd. 
In Eisai, the compound at issue belonged to a class of drugs known as proton pump 
inhibitors that suppress gastric acid production.
133
 The Omeprazole or Prilosec
®
 is a blockbuster 
drug of this class for heartburn or other symptoms.
134
 Eisai Co., Ltd. and Eisai, Inc. (Eisai) 
owned a patent claiming rabeprazole, an active ingredient in Aciphex, a drug approved by the 
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FDA for the treatment of duodenal ulcers, heartburn, and associated disorders.
135
 Rabeprazole 
was challenged by ANDA filers as unpatentable for obviousness over a prior art compound 
lansoprazole.
136
 Lansoprazole was disclosed in a European patent as a compound for ulcer 
treatment.
137
 It is structurally identical to rabeprazole, except at the 4-position on the pyridine 
ring, lansoprazole has a trifluoroethoxy (OCH2CF3) substituent, while rabeprazole has a 
methoxypropoxy (OCH2CH2CH2 OCH3) substituent (see structure below).
138
 The district court 
found a PHOSITA would not have selected lansoprazole as a lead compound in the search for 
antiulcer compounds.
139
 Although lansoprazole’s anti-ulcer activity is twenty times superior to 
omeprazole, the district court emphasized on the difference between anti-ulcer action and gastric 
acid inhibition. The district court noted a PHOSITA searching for a gastric acid inhibitor would 
not have considered the anti-ulcer data to determine the acid inhibition activity.
140
 The Federal 
Circuit found this distinction not dispositive in determining whether a PHOSITA would have 
selected lansoprazole as the lead compound.
141
 Nonetheless, it agreed with the district court that 
because the fluorinated substitute in lansoprazole provided for enhanced lipophilicity (an 
advantageous property of a compound to cross lipid membrane),
142
 a PHOSITA would not have 
been motivated to modify lansoprazole in such a way to remove the fluorinated substituent that 
gave the advantageous property.
143
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iv. Altana Pharma AG v. Teva Pharm. USA, Inc. 
In Altana, the Federal Circuit found a PHOSITA would have been motivated to select the 
prior art compound as the lead compound. The chemical compound at issue belongs to a class of 
drugs known as proton pump inhibitors that suppress gastric acid production.
144
 Omeprazole or 
Prilosec
®
 is a blockbuster drug of this class for heartburn or other symptoms.
145
 Altana Pharma 
AG and Wyeth (Altana) owned a U.S. patent No. 4,758,579 (the ‘579 patent) claiming 
pantoprazole, the active ingredient in Altana's antiulcer drug Protonix
®
.
146
 Teva filed an ANDA 
for the FDA approval of a generic Protonix
®
, and also filed a paragraph IV certification 
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challenging the validity of the ‘579 patent.147 In considering Altana’s motion for preliminary 
injunction, the district court found Teva had raised a substantial argument that a PHOSITA 
would have selected a prior art compound 12 as the lead compound.
148
 Compound 12 was 
disclosed in a U.S. Patent No. 4,555,518 (‘518 patent), and the patent compared the effectiveness 
of eighteen claimed compounds, including compound 12, against prior art compounds of the 
class of proton pump inhibitors.
149
 The Federal Circuit agreed with the district court that 
compound 12 was a natural choice for further development, and noted that the claimed 
compounds were improvement over the prior art, especially omeprazole.
150
 In addition, 
compound 12 was one of the more potent of the eighteen compounds in the ‘518 patent with the 
activity data.
151
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v. Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc. 
Similarly, in Bristol-Myers Squibb (BMS) mentioned at the beginning of this article, the 
court found the prior art could be considered as the lead compound. The Federal Circuit affirmed 
the district court decision that a PHOSITA would have selected 2’-CDG as the lead compound 
for further research.
152
 The court examined the state of the antiviral drug discovery at the time of 
the invention, and noted that research on carbocyclic analogs was a focus for antiviral activity.
153
 
At that time, 2’-CDG generated a lot of interests among researchers from reporting on its better 
antiviral activity against the herpes virus than Ara-A, an FDA-approved best selling drug at that 
time, and its excellent activity against the hepatitis B virus.
154
 Therefore, 2’-CDG was a natural 
choice.
155
 Even though 2’-CDG was discovered to be highly toxic later, which would prevent a 
PHOSITA to select it as a lead compound, the court noted that at the time of the invention, the 
high toxicity was not yet known to the scientific community.
156
 On the contrary, the prior art 
showed 2’-CDG was generally understood at the time of the invention to be safe and nontoxic.157 
Because the perspective of a PHOSITA at the time of the invention was the relevant 
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consideration,
158
 the PHOSITA would have been motivated to select 2’-CDG as the lead 
compound for further development.
159
 
  Entacavir:     2’-CDG: 
N
N
N NH
NH2
O
HO
HO
 
N
N
N NH
NH2
O
HO
HO
 
After the court determines that a PHOSITA would have been motivated to select the prior 
art compound as the lead compound, it then examines whether the PHOSITA would have been 
motivated to modify the lead compound to make the claimed new compound. 
2. Motivation to Modify 
In Altana, the district court found there was a motivation to modify the prior art 
compound 12 in the prior art to arrive at the claimed invention.
160
 One prior art taught a pKa 
value
161
 of four would be desirable for an effective PPI because of a better stability of the 
compound in the body.
162
 Another prior art article disclosed pKa values of different compounds, 
and taught a lower pKa value would be resulted from a methoxy group (-OCH3) at the 3-position 
of the pyridine ring than from a methy group (-CH3) at the same position.
163
 The Federal Circuit 
affirmed the district court decision and found the first prior art motivated a PHOSITA to modify 
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the prior art compounds to reduce pKa values to 4, and the second prior art provided the specific 
teaching to reduce the pKa value in the direction leading to the claimed compound.
164
 
In Takeda, the court found a PHOSITA would not be motivated to modify compound b to 
achieve the claim invention.
165
 To make pioglitazone from compound b, a PHOSITA would have 
to replace the methyl group with an ethyl group on the pyridyl ring, and then move the ethyl 
group from the 6-position to the 5-position.
166
 The court found nothing in the prior art suggested 
such specific modifications and the process was not routine at the time of the invention.
167
 Since 
there were wide choices of substituents on the pyridyl ring, such as chloride, fluoride or others, a 
PHOSITA would not be motivated to select a methyl group.
168
 Based on the prior art article 
teaching, adding a methyl group would not decrease unwanted side effects, so the court found 
there was no reasonable expectation that the methyl group would enhance its property in body 
weight and brown fat weight.
169
 Due to the lack of the reasonable expectation of success, the 
court concluded that a PHOSITA would not be motivated to modify compound b to make the 
claimed compound.
170
 
In BMS, the court found with 2’-CDG as the lead compound, a PHOSITA would be 
motivated to modify its carbocyclic ring by substituting an exocyclic methylene group at the 5’ 
position to made entecavir.
171
 The expert testimony explained small changes on the 2’ or 5’ 
position of the carbocyclic ring were obvious choices to make to modify the lead compound.
172
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Prior art references also disclosed that exocyclic methylene substitution at the 5’ position on the 
carbocyclic ring of a structurally similar compound led to superior antiviral properties.
173
 
Therefore, in light of the prior art and a PHOSITA’s knowledge, it was obvious to modify 2’-
CDG to make the claimed compound, and the modification was from a small and finite number 
of changes to try to get to the invention.
174
 Since structurally similar compounds generally have 
similar properties, a PHOSITA would have a reasonable expectation of success based on the 
properties of prior art compounds.
175
 
B. LCA in USPTO Proceedings 
The USPTO proceedings provide mechanisms for parties to appeal Patent Examiner’s 
adverse decisions in patent applications and reexamination proceedings, and to challenge the 
patentability of issued patents.
176
 The Patent Trial and Appeal Board (PTAB) is the 
administrative law body of the USPTO,
177
 and it has applied the LCA in the proceedings. 
1. USPTO Proceedings 
The proceedings at the Patent Office include ex parte appeal to the PTAB
178
, ex parte 
Reexamination (EPR), Post Grant Review (PGR), Inter Partes Review (IPR), Transitional 
Program for Covered Business Method Patents, Derivation Proceeding
179
 and other proceedings.  
In an ex parte appeal, a patent applicant or owner appeals to the PTAB Patent Examiner’s 
final rejection of a patent application or patent in a reexamination.
180
 The appellant can 
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overcome the examiner’s rejection by preponderance of evidence that the examiner was error in 
the underlying finding of fact or the reasoning used to establish the prima facie obviousness.
181
  
The EPR proceedings generally involve only the patent owner and the USPTO. Through 
EPR, the patent owner may request an USPTO examination of an issued patent based on prior art 
the owner brings to the USPTO’s attention. If the owner establishes a substantial and new 
question of patentability (SNQ), the PTO will grant the request and order reexamination of the 
patent. The patent owner can appeal the final decision to the PTAB, and then to the Federal 
Circuit. 
In PGR, a third party (a person who is not the owner of the patent) files a petition to the 
PTAB on or within nine months after the patent is issued or reissued.
182
  If the party can show 
that it is more likely than not that at least on claim challenged is unpatentable, the PTAB may 
institute the review and make a final determination within one year.
183
 The PGR generally 
applies to patents issued under the first-inventor-to-file provisions of the American Invents Act 
(AIA).
184
 
In IPR, a third party files a petition to the PTAB, and in the case of first-inventor-to-file 
patents, the time for file is after nine months of the patent’s issuance or reissuance, or after the 
termination of the PGR if a PGR is instituted, whichever is later.
185
 For first-to-invent patents, 
the party can file at any time.
186
 If the party can show there is a reasonable likelihood he would 
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prevail with respect to the patentability of at least one claim challenged, the PTAB may institute 
the review and make a final determination within one year.
187
 The only ground of unpatentability 
the party can raise is under section 102 and 103, and only on prior art that is patent or printed 
publications.
188
  
2. The Application of LCA by PTAB 
i. LCA Is Not Required in Every Chemical Case 
In Ex Parte Argade, patent applicants appealed the Patent Examiner’s rejection of patent 
claims to the PTAB.
189
 Claim 1 of the patent at issue claims compounds as protein kinase 
inhibitors with the formula I:
190
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Claim one was rejected for obviousness because a prior art reference disclosed a generic group 
of compounds that encompassed the claimed compounds, and were useful as pharmaceutical 
therapeutic agents for the treatment disease such as cancer.
191
 The Examiner found one example 
of a specific compound in the prior art reference was structurally similar to the claimed 
compounds.
192
 The patent applicants contended the Examiner did not establish a prima facie case 
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of obviousness because the prior art did not expressly disclose any particular compound as a lead 
compound, nor provided compounds’ activity or potency data for a PHOSITA to select the 
compound as lead compound.
193
 The PTAB disposed of the argument that the Examiner has to 
follow the LCA in this situation, and noted that the LCA applied in the context of claims to a 
specific compound as in Otsuka and Daiichi.
194
 In this case, claim 1 is a genus claim covering a 
large number of chemical compounds, so the Dillon analysis is more appropriate.
195
 Since the 
prior art compounds were useful for the same purpose as the claimed compound and fell under 
the scope of generic claim 1, and the Examiner also identified in the prior art some motivation to 
modify the compounds, the PTAB concluded there was no error in Examiner’s rejection of the 
claim for obviousness ground.
196
 
 The PTAB also found the LCA might not be proper for the obviousness analysis of 
composition claims. Composition claims are claims that “include ‘all compositions of two or 
more substances and . . . all composite articles, whether they be the results of chemical union, or 
of mechanical mixture, or whether they be gases, fluids, powders or solids.’”197 
 In Ex Parte Gaffar, the claim at issue is a composition claim for oral treatment, and it 
reads:  
1. An oral care composition comprising about 0.1 % to about 5% of a tocopherol 
component, wherein the tocopherol component consists of about 50% to about 90% by 
weight of gamma tocopherol and the balance of the tocopherol component is selected 
from alpha tocopherol, beta tocopherol, delta tocopherol, and mixtures thereof.
198
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The Examiner rejected the claim as obvious over prior art Hansenne.
199
 Hansenne taught 
tocopherol/melanin[-]like pigment combination was useful for oral and dental use, and the 
combination included a “mixture of a-tocopherol, β -tocopherol, γ-tocopherol and δ-tocopherol 
in a ratio of 25/25/25/25, dissolved in soya oil at a concentration of 50%.”200 Patent applicants 
appealed the decision to the PTAB and contended that the lead compound (or lead formulation) 
analysis was required.
201
 Under the analysis, the applications alleged, the prior art had to include 
specific subject matter, not hypothetical and unexemplified examples or combinations selected 
with hindsight.
202
 The applicants contended Hansenne did not teach or suggest a tocopherol 
component with 50% to 90% of gamma tocopherol by weight.
203
  
 The PTAB affirmed Examiner’s rejection and found LCA was not required for a 
composition or formulation claim.
204
 Although the Federal Circuit had stated in Unigene Labs., 
Inc. v. Apotex, Inc. that the obviousness analysis in the chemical art was often based on a lead 
compound and “that in the context of a composition or formulation patent the ‘lead compound’ 
might more appropriately be referred to as a ‘reference composition,’” the PTAB found the two-
prong LCA analysis was not required in every composition or formulation claim analysis.
205
  
 Similarly, the PTAB declined to follow the LCA in another case of composition claims 
directed to a dietary supplement.
206
 The PTAB agreed with the Examiner that the rationale for 
obviousness analysis of a chemical compound is “entirely different than that of compositions.”207 
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“A single chemical change on a compound can render a drug much improved or useless for its 
purpose. The addition or subtraction of a component does not alter the ability of the composition 
to serve as a dietary supplement.” The obviousness of components of a composition or claimed 
range of the components can be based on rationale, case law and guidance, not a single specific 
composition in the prior art.
208
 
ii. LCA Is Required for Obviousness of New Chemical Compound 
 Although the USPTO does not require the LCA in every chemical genus or composition 
case, it requires the LCA in the obviousness analysis of new chemical compounds.  
In Apotex Inc. v. Merck Sharp & Dohme Corp., Apotext filed a Petition for an IPR to 
challenge Merck’s patent covering fosaprepitant dimeglumine, which is useful for treating 
inflammatory diseases, pain or migraine, asthma, and emesis, and is the active ingredient in 
Merck’s FDA-approved drug Emend® for Injection.209 Apotex claimed that fosaprepitant 
dimeglumine was obvious over prior art compounds, especially a specific example, compound 
96 disclosed in a prior patent.
210
  
 The PTAB made it clear that the LCA is generally required in a case of new chemical 
compound, and stated “[e]ven ‘post-KSR, a prima facie case of obviousness for a chemical 
compound still, in general, begins with the reasoned identification of a lead compound.’”211 In 
determining whether a PHOSITA would have selected the Compound 96 as the lead compound, 
the PTAB followed the reasoning of the Federal Circuit in Otsuka and Altana, as determined by 
the pertinent properties of the prior compound.
212
 The PTAB noted Compound 96 was among 
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the “laundry list” of 601 compounds disclosed in the prior art and there was no reported activity 
data for those compounds, so there was no reason for a PHOSITA to select any of the 
compounds as a lead, and compound 96 could not be “a natural choice for further 
development.”213 Therefore, the PTAB denied the institution of inter partes review by 
concluding that Apotex had not established a reasonable likelihood that it would prevail in 
showing the unpantentavility of the claim.
214
 
 Similarly, in Ex Parte Caligiuri, the PTAB emphasized the importance of the pertinent 
properties in selecting the lead compound even though the identified lead compound was among 
twenty compounds listed in the prior art.
215
 In this case, the Examiner identified compound 0477 
in the prior art as structurally related to the claimed compound and was specifically identified in 
the prior art among other 19 listed compounds.
216
 In reversing the Examiner’s Final Rejection on 
obviousness of the claimed compounds, the PTAB reasoned that absence any functional data of 
compound 0477, or suggestion that 0477 provided any benefit or special property as compared to 
others disclosed compounds in the prior art, the identification of 0477, even among a small 
number of compounds, was not sufficient for a PHOSITA to select compound 0477 as the lead 
compound.
217
  
 Once pertinent properties are disclosed in the prior art, the PTAB is likely to find that 
there is sufficient motivation for a PHOSITA to select any of the structurally similar compounds 
identified in the prior art.  
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 In Ex Parte Demattei, patent owners appealed the Examiner’s rejection of a patent 
claiming hydrogen sulfate salts.
218
 The Examiner found the claimed salts were obvious over a 
prior art patent’s disclosure of a structurally similar compound 29c.219 The prior art also 
disclosed the MEK1 inhibition activity of a list of compounds, and twelve compounds, including 
compound 29c, were identified as active with an IC50 value of less than 50μm.220 The PTAB 
found any of the disclosed twelve compounds could be selected by a PHOSITA to serve as lead 
compounds.
221
  
 Similarly, in Ex Parte Baranowska-Kortylewicz, the PTAB found any of the six 
compounds highlighted in the prior art reference could have been looked at by a PHOSITA as 
lead compounds even though the properties of some compounds might be “detrimental” to their 
therapeutic effect.
222
 In this appeal of Examiner’s rejection, the invention relates to compounds 
that produce cytotoxic effect and/or detectable via medicine imaging techniques by being 
incorporated into nucleus of malignant tumor cells.
223
 A prior art reference disclosed a general 
formula of conjugate and six specific examples having similar formulas as the invented 
compounds.
224
 The prior art described the conjugates were capable of targeting tumor cells and 
being incorporated into the nuclear material to produce a cytotoxic effect.
225
 The testing data 
showed that the example 1 was very effective, but had a short half-life, which might be 
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“detrimental to the delivery of therapeutic dose to tumor.”226 However, the prior art also stated 
the short half-life could be beneficial due the possibility of repeated injection without a large 
radioactive burden in normal tissue.
227
 The prior art also disclosed that example 2 could not cross 
cell membrane by itself and required transport mechanism because of its hydrophilicity, while 
example 5 was the most hydrophobic and might be best suited for local administration.
228
 Citing 
Otsuka, the patent owner contended a PHOSITA would not have selected example 1 or 2 as lead 
compounds because of their nonbeneficial properties, and the prior art taught away from 
selecting them.
229
 Instead, example 5 is the natural choice for further development.
230
 The PTAB 
disagreed and found the prior art taught the compounds were useful for their “cytotoxic effect 
and/or . . . radioimaging techniques.”231 Although example 1 had short half-life and example 2 
was hydrophilic, the prior art clearly taught the means to overcome the problems, so a PHOSITA 
would not have been dissuaded to select them as lead compounds.
232
 Also citing Otsuka, where 
the Federal Circuit “expressly acknowledges the possibility that there can be ‘one or more lead 
compounds,” the PTAB found any one of the six examples could be selected as the lead 
compound by a PHOSITA.
233
 
3. The Differences Between the Court Decisions and USPTO Decisions 
 Because the USPTO follows the Federal Circuit decisions, the PTO has applied and 
followed the LCA in its obviousness analysis in the chemical art. For example, both Federal 
Circuit and the USPTO emphasized the importance of the pertinent property data in the prior art 
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for a PHOSITA to select the prior art compound as the lead compound. However, there are a few 
noticeable differences. 
 First, the USPTO explicitly stated LCA is not required for the obviousness analysis of 
every genus and composition claims.
234
 This is in contrast with the Federal Circuit’s approach in 
Unigene Labs, Inc. v. Apotex, Inc. In Unigene, Unigene Laboratories, Inc. and Upsher–Smith 
Laboratories, Inc. (Unigene) owned a patent claiming an FDA approved nasal spray Fortical® 
with the active ingredient salmon calcitonin, a natural polypeptide hormone.
235
 Apotex filed an 
ANDA and contended the composition claim in Unigene’s patent was obvious over prior art, 
including Novartis International AG's Miacalcin® calcitonin nasal spray.
236
 Fortical® and 
Miacalcin® have the same active ingredient and are bioequivalent, but they have different 
formulations.
237
 Miacalcin® contains benzalkonium chloride (BZK) as a preservative, absorption 
enhancer and surfactant.
238
 Fortical® contains 20mM citric acid as an absorption enhancer and 
stabilizer/buffer, polyoxyethylene(2) sorbitan monooleate as a surfactant, and phenylethyl 
alcohol and benzyl alcohol as preservatives.
239
 The court followed the LCA and found 
Miacalcin® served as the reference composition for the development of the claimed composition 
because they had the same function and pharmaceutical properties.
240
 However, the court found 
there was no reason or motivation for a PHOSITA to replace BZK in Miacalcin® with 20 mM of 
citric acid in the normal course of research and development of nasal calcitonin formulation, and 
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would not make a combination of citric acid with polyoxyethylene(2) sorbitan monooleate, 
phenylethyl alcohol and benzyl alcohol.
241
 
Although the Federal Circuit has not ruled the LCA is required for the obviousness 
analysis of each chemical composition or formulation patent, it followed the LCA in Unigene 
and referred the lead compound equivalent of chemical composition as “reference 
composition.”242 However, in multiple USPTO cases, the PTAB has found the LCA was 
inapplicable in the obviousness analysis of those genus and composition claims, and reasoned 
that structural changes of chemical compound could have much more impact on the function and 
properties of a drug than impact of formulation changes on the drug.
243
 The PTAB noted 
“[i]ndeed, Unigene cannot run counter to the flexible analysis set out by the Supreme Court in 
KSR that recognizes the obviousness of pursuing known options within the technical grasp of the 
skilled artisan.”244 
 The second difference is that once prior art has sufficient disclosure of prior art 
compounds’ pertinent properties, in USPTO’s view, all those compounds could serve as lead 
compounds, and the USPTO does not examine further in detail whether a PHOSITA would pick 
one or a few of the limited number of disclosed compounds. In Ex Parte Demattei, the PTAB 
found any of the twelve compounds disclosed in the prior art with MEK1 inhibition activity 
could be selected by a PHOSITA as lead compounds.
245
 Similarly, in Ex Parte Baranowska-
Kortylewicz, the PTAB found any of the six compounds highlighted in the prior art reference 
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could have been looked at by a PHOSITA as lead compounds even if some of them presented 
negative properties such as short half-life or difficulty in crossing membrane.
246
  
However, in Otsuka, the Federal Circuit found in the eleven compounds identified in the 
prior art with mouse jumping test data, the fifth potent compound would not have been 
considered by a PHOSITA as a lead compound because of the other four more attractive lead 
compound candidates. Also, the court tends to find that any negative properties of the prior art 
compound could dissuade the PHOSITA to select the prior art compound as the lead. Compound 
b’s effect in increasing body weight and brown fat weight in Taketa led the court to conclude 
there was no motivation to select compound b.
247
 This is in contrast with the result in Ex Parte 
Baranowska-Kortylewicz, where the PTAB found the short-half life and hydrophilicity of the 
prior art compounds did not teach away the selection of the compounds as lead compounds.
248
 
Although the Federal Circuit has recognized the possibility of “one or more lead compounds,” 
courts appear to have narrower focus on the lead compound.
249
 
 The more relaxed application of the LCA at the USPTO may be due to the different 
evidentiary burden of the proceedings. In court litigations, a patent is presumed to be valid.
250
 
The accused infringer has the burden to show every element of the obviousness of the patent by 
clear and convincing evidence.
251
 Thus, in the LCA, the infringer has to prove by clear and 
convincing evidence that a PHOSITA would have selected the presented prior art compound as 
the lead compound, and by clear and convincing evidence that the PHOSITA would have 
modified the lead compound in a specific way to achieve the patented compound.  In PTO 
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proceedings, there is no presumption of validity of the challenged patents. The standard of proof 
for ex parte appeal is preponderance of evidence, and reasonable likelihood of prevailing for IPR 
proceedings. The patent challenger only needs to prove it is reasonably likely the PHOSITA 
would have selected the compound and modified the compound to make the new chemical 
compound. The standard is lower than the clear and convincing evidence in court proceedings, 
which explains why the PTAB tends to find all limited number of compounds with favorable 
properties are possible lead compounds. 
V. THE LCA IS PROPER AND CONSISTENT WITH THE KSR RATIONALE 
 Since the Federal Circuit adopted the LCA and continued to use it in post-KSR decisions, 
the LCA has been criticized by many as rigid and bright line rule that is inconsistent with the 
KSR flexible requirement.
252
 However, the LCA is required by the technology and modern drug 
discovery process, and a analysis of the court decisions shows the LCA is not inconsistent with 
KSR.  
A. The LCA Is Determined by the Modern Drug Discovery Process 
 The LCA was developed with the modern drug discovery development, and it is 
consistent with the process of target identification and validation, high throughput screening, hit-
to-lead and optimization steps. As illustrated before, the modern discovery is no longer based on 
accidental discovery or scientists’ imagination, but a target oriented rational drug discovery. 
Under the traditional approach, a scientist may pick an interested molecule without knowing the 
mechanism of the action, and makes some random modifications to the structure, in the hope this 
would lead to compounds with similar or more potent activities. If the scientist is fortunate 
enough, his efforts may eventually lead to the development of a drug.  
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 Under the modern approach, the target protein was studied and the mechanism of its 
interaction with certain classes of chemical compounds was understood first. Based on the 
knowledge of the target protein and prior art disclosure of the chemical classes likely to have 
activity at the target site, library compounds are prepared and screened to yield hits series. After 
further analysis and screening, the hits were narrow further to give more potent and selective 
compounds, with less toxicity and other side effects, but with desirable absorption, distribution, 
metabolism and excretion. Therefore, the selection of compounds for further development is a 
rational, property-based process rather than a random, serendipitous process under the traditional 
approach. 
 This higher intellectual input in the modern drug discovery is consistent with the higher 
requirement of finding of obviousness under the LCA than the “structural similarity” approach. 
Under the LCA, a reason or motivation is required for a PHOSITA to select the prior art 
compound as the lead compound for further development. In the property driven drug discovery 
process, a PHOSITA faces with a large number of chemical compounds, either prepared by 
himself, or from literature and patent precedents, sometimes thousands of compounds with 
potential favorable activities. The PHOSITA needs to make choices based on knowledge of the 
target and compounds’ properties, not just potency and selectivity, but also toxicity and other 
unfavorable side effects, as well as ADME properties. If there is no property data or other 
motivations, it is impossible for a PHOSITA to go further in the process. He or she would not 
randomly choose compounds for further development, and hope they make to the final drug. 
 The LCA also requires a motivation to modify the prior art compound to arrive at the 
claimed compound. This is determined by the drug discovery process as well as the 
characteristics of chemical art. During drug discovery, modification of chemical structures 
  41 
happens at every stage from hit identification, hit-to-lead and lead optimization. A PHOSITA has 
to modify compounds based on the properties from the assays, from the interaction of the 
compounds with the target, and from the knowledge and experience of chemical synthesis. 
Because the infinite possibility of variations of a chemical structure, a PHOSITA needs to know 
which part of a chemical structure should be modified and at which position; which substituents 
are suitable to obtain favorable properties; which chemical modification is easy to synthesize and 
suited for large scale productions. Each decision requires input from different expertise, and thus 
the resulting chemical compounds are not the result of a simple, random modification, but an 
intense intellectual process. 
B. LAC Is Consistent with KSR 
 Although the LCA requires reason or motivation to select and modify lead compounds, it 
is not in conflict with the KSR decision, and courts have considered various factors consistent 
with the KSR rational in applying the LCA.  
1. Motivation Requirement Is Consistent with KSR 
 Although the TSM was rejected as the exclusive approach for obviousness analysis by 
the Supreme Court, “the Court acknowledged the importance of identifying ‘a reason that would 
have prompted a person of ordinary skill in the relevant field to combine the elements in the way 
the claimed new invention does’ in an obviousness determination.”253 As the Federal Circuit 
noted, the Supreme Court in KSR for the obviousness analysis assumed a PHOSITA would 
recognize a problem and pursues potential solutions, and there would be a reason or motivation 
for the PHOSITA to make particular modifications and to narrow the prior art scope to a limited 
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number of predictable solutions.
254
 Whether the reason is the demand from the marketplace, any 
need or problem in the field, knowledge or common sense of the PHOSITA, there exists such a 
reason or motivation to choose the prior art elements and combine or modify such elements to 
arrive at the claimed invention. A PHOSITA would not just pick some elements from prior art 
without any reason and then combine or modify them. Even for the “obvious to try” rationale, 
the motivation comes from the “identified, predictable” solution within the PHOSITA’s reach.255  
 In the case of chemical art, it is especially important for a PHOSITA in the drug 
discovery process to have some reason or motivation to select and modify the prior art 
compounds. This is determined by the problem or difficulty in the drug discovery, the complicity 
of the process, and the intellectual requirement in each step of the process. Also, because of the 
nature of chemical art, a slight variation of a chemical structure can lead to completely different 
properties. The solutions to a chemical problem are likely unpredictable, and anticipated results 
are less likely in the chemical art. This is especially true in the drug discovery field since any 
negative property or side effect could lead to the failure of the program. Therefore “post-KSR, a 
prima facie case of obviousness for a chemical compound still, in general, begins with the 
reasoned identification of a lead compound,”256 and “it remains necessary to identify some 
reason that would have led a chemist to modify a known compound in a particular manner to 
establish prima facie obviousness of a new claimed compound.”257  
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2. KSR Rationales Are Considered in LCA 
In consistent with the KSR, the Federal Circuit has stated the motivation does not have to 
explicitly come from the prior art, and it can come from any number of sources.
258
 
i. The Number of Compounds Disclosed 
 In determining whether a PHOSITA would have select the prior art compound as the lead 
compound, both Federal Circuit and the PTO have considered the disclosure of the prior art as a 
whole. The number of potential lead compounds disclosed in the prior art is an important factor 
in the consideration. In Altana, the Federal Circuit noted compound 12 was disclosed in the prior 
art among seventeen other compounds with improved activity over omeprazole, and compound 
12 was one of the more potent of the eighteen compounds in the prior art with the activity 
data.
259
 The court concluded the defendant had raised a substantial question that a PHOSITA 
would have selected the more potent compounds among the eighteen compounds, including 
compound 12 as the lead compound.
260
 
 However, when there are a large number of options in the prior art, the court is less likely 
to find a compound to be a lead compound. In Otsuka, where the prior art included a laundry list 
of compound with potential central nervous system controlling properties, and the presented lead 
compound was buried in hundreds of examples, the presented compound was not considered a 
lead compound.
 261
 
 Therefore, by considering the number of the potential lead compounds disclosed in the 
prior art, courts and the PTO followed the KSR’s rationale that when there are “finite number of” 
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solutions, a PHOSITA would likely pursue one or more of the solutions.
262
 This is not a 
motivation explicitly from the prior art, but from the knowledge or common sense of the 
PHOSITA, which is consistent with the KSR’s flexible requirement.  
ii. State of the Art and the Knowledge of the PHOSITA 
In determining the obviousness of the chemical compound, the Federal Circuit considered 
the state of the art at the time of the invention, not just the teaching of the specific prior art, for a 
PHOSITA to select and modify the prior art compounds.  
In BMS, the structure of entecavir contains a “carbocylic ring.”263 The court examined the 
scientific literatures during the relevant time period before the claimed invention, and found that 
carbocyclic analogs were of great interest to scientists in search of compounds with antiviral 
activity at that time.
264
 There were extensive research and publications on carbocyclic analogs 
and 2’-CDG (one of the analogs) for their antiviral activities.265 2’-CDG was a hot molecule 
because of its potency and non-toxicity, and it was treated by different researchers as exciting 
and promising compound to work with.
266
 The expert testimony also showed 2’-CDG’s 
prominence during the relevant time frame.
267
 These evidence on the state of the antiviral drug 
research on carbocyclic analogs gave the court sufficient ground to find a PHOSITA would have 
selected the carbocyclic analog 2’-CDG as the lead compound.268 Here, among the various 
antiviral drug discovery approaches, the research on the carbocyclic analogs as a promising area 
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during the time of the invention narrowed the focus in the search of the lead compound, and 
provided the motivation to select 2’-CDG.  
In BMS, the court also found the motivation to modify 2’-CDG from the knowledge of 
the PHOSITA.
269
 From expert testimonies, the court noted small, conservative changes to the 2’-
CDG structure were well within a PHOSITA’s reach. Based on the PHOSITA’s knowledge, he 
or she could identify the specific part of the structure to make changes for better activity and 
easy synthesis.
270
 The PHOSITA would then combine his knowledge and the prior art disclosure 
to make the changes at the specific site, and the options were finite and easily traversed.
271
 
These considerations by the court follow KSR’s flexible requirement that any problem or 
need in the field, interrelated teachings of prior art reference, or background knowledge of a 
PHOSITA could provide the reason or motivation to combine or modify the prior art elements. 
iii. Obvious to Try 
In KSR, the Supreme Court noted if “there are a finite number of identified, predictable 
solutions,” it is obvious for a PHOSITA to try the combination, and “[i]f this leads to the 
anticipated success, it is likely the product not of innovation but of ordinary skill and common 
sense.
272
 Because chemical art is generally an unpredictable art, it is difficult for a PHOAITA to 
identify a finite number of predictable solutions. KSR's obvious to try “may present a difficult 
hurdle because potential solutions are less likely to be genuinely predictable.”273  However, the 
Federal Circuit has incorporated this obvious to try rationale in the application of the LCA under 
certain circumstances.  
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In examining the motivation to select lead compounds, courts and the USPTO have 
recognized the limited number of potential lead compounds disclosed in the prior art presents a 
situation of finite number of solutions, so a PHOSITA would likely pursue one or more of the 
solutions.
274
 
Takeda and BMS illustrate the applicability of the obvious to try rationale in the analysis 
of the motivation for chemical modifications. In Takeda, the Federal Circuit found the process of 
replacing the methyl group with an ethyl group on the pyridyl ring of the prior art compound and 
moving the ethyl from the 6-position to the 5-position was not routine at the time of the 
invention.
275
 A PHOSITA would have to look at various substituents, such as chlorides, halides, 
and other groups, not just methyl in modifying the pyridyl ring.
276
  There were infinite number of 
substituents to consider, and there were no expectation of success in reducing or eliminating 
toxicity of compound b by any particular substituent, so a PHOSITA would not be motivated to 
modify in this particular way.
277
 Because there were no finite number of solutions and no 
anticipated success for the modification, the modification would not have been obvious to a 
PHOSITA.  
In contrast, the addition of a single carbon atom to form an exocyclic methylene with the 
carbon atom at the carbocyclic ring of 2’-CDG in BMS was a modification within a small, finite 
number of changes to try to arrive at the claimed compound entecavir.
278
 The expert testimony in 
BMS showed that in considering whether to modify 2’-CDG’s carbocyclic ring or its guanine 
base, experts agreed carbocyclic ring would be a natural decision because of possible greater 
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activity from this modification.
279
 After this decision, the court found a PHOSITA would then 
make changes on either the 2’ or 5’ position on the carbocyclic ring because these are the only 
positions where small modifications are possible.
280
 As to what small changes to make, the court 
found the disclosure of the prior art, the properties of other antiviral compounds, and the strategy 
in synthesis narrowed the choice of changes to a finite number of solutions.
281
 Because 
structurally similar compounds often have similar properties, there was reasonable expectation of 
success at the time of the invention.
282
 In this analysis, the court considered the knowledge of the 
PHOSITA and the disclosure of the prior art to narrow the potentially infinite solutions to a finite 
number. Because of the reasonable expectation of success, the solutions were obvious to try. 
VI. CONCLUSION  
As drug discovery evolves from a serendipitous discovery to rational design and 
discovery, the obviousness analysis of chemical compounds evolves from structural similarity 
determinative to property determinative. The Lead Compound Analysis was in response to the 
development of modern drug discovery. It requires a patent challenger to prove a PHOSITA 
would have been motivated to select the prior art compound as the lead compound for further 
development, and would have been motivated to modify the compound to make the claimed 
invention. Although courts and the USPTO require different burden of proof to establish a prima 
facie obviousness, they have generally applied the LCA consistently to require the property data 
or other motivations to select the prior art compound as the lead and to modify the compound.  
The LCA has been criticized as rigid and inconsistent with the KSR decision. However, 
the LCA is determined by the nature of chemistry, and the development of technology and drug 
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discovery. A reason or motivation is required in every step of the drug discovery, from design of 
the chemical compound, hit identification, hit to lead and lead optimization. Analysis of the KSR 
and the LCA cases reveals that the motivation requirement is not in conflict with the KSR 
decision. Consideration of various factors by courts and the USPTO in the analysis, including the 
number of compounds disclosed in the prior art, the interrelated teaching of the prior art 
references, the state of the art at the time of the invention, knowledge of the PHOSITA, and the 
obvious to try approach, demonstrates the LCA is proper and in line with the KSR decision.  
 
 
 
